Roth Capital Cuts Allena Pharmaceuticals (NASDAQ:ALNA) Price Target to $31.00

Allena Pharmaceuticals (NASDAQ:ALNA) had its price target cut by Roth Capital from $61.00 to $31.00 in a research report sent to investors on Thursday morning, The Fly reports.

Other analysts also recently issued reports about the stock. ValuEngine raised shares of Allena Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 1st. Credit Suisse Group reiterated an outperform rating and set a $26.00 target price on shares of Allena Pharmaceuticals in a research report on Monday, August 5th. Cowen reissued a buy rating on shares of Allena Pharmaceuticals in a report on Friday, May 10th. Zacks Investment Research lowered shares of Allena Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 30th. Finally, Wedbush reaffirmed a buy rating and issued a $36.00 target price on shares of Allena Pharmaceuticals in a research note on Tuesday, July 2nd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Allena Pharmaceuticals currently has an average rating of Buy and a consensus price target of $23.14.

ALNA stock opened at $4.01 on Thursday. The company has a quick ratio of 7.83, a current ratio of 6.80 and a debt-to-equity ratio of 0.22. Allena Pharmaceuticals has a 12 month low of $3.62 and a 12 month high of $12.00. The business has a 50 day simple moving average of $4.47.

Allena Pharmaceuticals (NASDAQ:ALNA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.01). On average, equities research analysts predict that Allena Pharmaceuticals will post -2.04 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in ALNA. Wedbush Securities Inc. acquired a new position in Allena Pharmaceuticals in the second quarter valued at about $63,000. Sphera Funds Management LTD. raised its stake in Allena Pharmaceuticals by 24.9% in the first quarter. Sphera Funds Management LTD. now owns 431,193 shares of the company’s stock valued at $3,027,000 after purchasing an additional 85,994 shares in the last quarter. Deutsche Bank AG raised its stake in Allena Pharmaceuticals by 8.2% in the fourth quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock valued at $151,000 after purchasing an additional 2,118 shares in the last quarter. Squarepoint Ops LLC raised its stake in Allena Pharmaceuticals by 3.8% in the fourth quarter. Squarepoint Ops LLC now owns 43,500 shares of the company’s stock valued at $237,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Allena Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 72,314 shares of the company’s stock valued at $394,000 after purchasing an additional 5,444 shares in the last quarter. 79.70% of the stock is currently owned by institutional investors and hedge funds.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

See Also: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

The Fly

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.